Gamze Karataş

Gamze Karataş

Auto-generated profile, based on publicly available information

Gamze Karataş

University of Health Sciences Türkiye, İstanbul Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Ophthalmology, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2025 in Strabismus
Verified
Journal Article
Closed access
GKGamze Karataş
Gamze Karataş
MKMehmet Egemen Karataş
Mehmet Egemen Karataş
Objective: This study aims to evaluate and compare the accuracy and performance of two large language models (LLMs), ChatGPT-4.0 and DeepSeek-R1, in answering pediatric ophthalmology-related questions. Methods: A total of 44 multiple-choice questions were selected, covering various subspecialties of pediatric ophthalmology. Both LLMs were tasked with answering these questions, and their responses were compared in terms of accuracy. Results: ChatGPT-4.0 correctly answered 82% of the questions, while DeepSeek-R1 achieved a higher accuracy rate of 93% (p: 0.06). In strabismus, ChatGPT-4.0 answered 70% of questions correctly, while DeepSeek-R1 achieved 82% (p: 0.50). In other subspecialties, ChatGPT-4.0 answered 89% correctly, and DeepSeek-R1 achieved 100% accuracy (p: 0.25). Conclusion: DeepSeek-R1 outperformed ChatGPT-4.0 in overall accuracy, particularly in pediatric ophthalmology. These findings suggest the need for further optimization of LLM models to enhance their performance and reliability in clinical settings, especially in pediatric ophthalmology.

18 February 2026 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
EÖEce Özal
Ece Özal
AOAbdullah Ozkaya
Abdullah Ozkaya
MAMurat Arıcı
Murat Arıcı
AKAnıl Korkmaz
Anıl Korkmaz
SESerhat Ermiş
Serhat Ermiş
MHMustafa Hepokur
Mustafa Hepokur
Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Türkiye: 48-Month Data, BOSPHORUS-DME Study Group Report No. 1 - Turkish Journal of Ophthalmology

5 January 2026 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
GKGamze Karataş
Gamze Karataş
AÇAkın Çakır
Akın Çakır
DYDilan Yıldız
Dilan Yıldız
MAMurat Arıcı
Murat Arıcı
AKAnıl Korkmaz
Anıl Korkmaz
AOAbdullah Ozkaya
Abdullah Ozkaya
Diabetic macular oedema (DME) is a leading cause of visual impairment worldwide. Real-world evidence is essential for understanding treatment effectiveness and guiding practical decision-making in routine clinical care. The aim of this work is to evaluate the cost-effectiveness of early versus late switching to intravitreal aflibercept or ranibizumab in eyes with DME refractory to intravitreal bevacizumab loading treatment. This multicentre retrospective study included treatment-naïve refractory DME eyes that initiated bevacizumab between 2021 and 2023. Eyes were divided into three groups: no switch, early switch (3-6 months), and late switch (after 6 months). Public healthcare costs from 2021-2023 were used to calculate the cost per 0.1 improvement in best-corrected visual acuity (BCVA) and per 100 μm reduction in central macular thickness. Cost-effectiveness ratio and incremental cost-effectiveness ratio analyses were performed. A total of 229 eyes in the no-switch group, 328 eyes in the early-switch group, and 63 eyes in the late-switch group were analysed. At month 12, the greatest BCVA gain was observed in the early-switch group (p = 0.02). Mean injection numbers were 5.7 ± 1.4 (no-switch), 7.2 ± 1.5 (early-switch), and 6.6 ± 1.4 (late-switch) (p < 0.001). Cost-effectiveness ratio for visual acuity improvement was €4,838, €10,395, and €10,848 for the no-switch, early-switch, and late-switch groups, respectively. Incremental cost-effectiveness ratio analysis showed additional costs of €15,654 for early switching and €54,856 for late switching compared with no switching. Central macular thickness reduction was greatest in the no-switch group and lowest in the late-switch group (p = 0.05). Although early switching yields the greatest visual improvement and faster rehabilitation, it incurs higher costs. The no-switch strategy provided modest visual improvement at the lowest cost, resulting in the most favourable cost-effectiveness ratio. Late switching produced limited benefit at high cost, rendering it an unfavourable option. Treatment decisions should balance clinical efficacy and cost-effectiveness on an individual basis.

1 January 2021 in Beyoglu Eye Journal
Verified
Journal Article
Open access
GKGamze Karatas
Gamze Karatas
KAKarata
Karata
BEBurak Erden
Burak Erden
ACAkin Cakir
Akin Cakir
ERErden
Erden
MEMustafa Nuri Elcioglu
Mustafa Nuri Elcioglu
This is a retrospective, comparative evaluation of the short-term efficacy and safety of intravitreal ranibizumab (IVR) and IVR combined with posterior subtenon triamcinolone acetonide (STA) in the treatment of diabetic macular oedema (DME). A total of 79 pseudophakic eyes of 57 patients with DME who underwent IVR injection treatment were examined retrospectively. All of the patients were treatment-naive. In the study group (STA+IVR), consisting of 30 eyes of 39 patients, the STA and IVR were administered in the first treatment session simultaneously, followed by 2 consecutive monthly IVR injections. In the control group (IVR only) comprised 40 eyes of 27 patients, 3 consecutive monthly IVR injections were administered. Patients with serous retinal detachment (SRD) according to optical coherence tomography images were identified in both groups for subgroup analyses. The primary outcome measures were changes in central macular thickness (CMT), best corrected visual acuity (BCVA), and the intraocular pressure (IOP) at 1, 2, and 3 months post-injection. There was no statistically significant difference between the demographic characteristics of the patients' baseline BCVA and CMT measurements (p>0.05). For the IVR group, the mean pre-treatment CMT and BCVA was 421.20±89.10 μm and 0.42±0.24 logMAR, respectively. After the third injection, the mean was 308.12±59.07 μm and 0.20±0.12 logMAR, respectively. The combined treatment group baseline measurements were 454.50±122.52 μm and 0.54±0.29 logMAR, respectively. After the third injection, the mean was 294.22±50.33 μm and 0.27±0.21 logMAR, respectively. The decrease was statistically significant for both groups (p=0.001). Comparison of the CMT within groups revealed a statistically significant difference in favor of the combined group after the second injection (p=0.017). There was no statistically significant difference in the BCVA gains between groups (p>0.05). Patients with SRD were evaluated as a subgroup, and at the first month, the mean gain in CMT was -71.63±57.98 μm in the control group and -123.61±93.46 μm in the study group (p=0.048). The required anti-glaucomatous treatment was statistically significant in the combined group (p=0.008). Both treatments provided improvement in BCVA and CMT and can be considered functional and anatomically effective treatment options for DME.

18 February 2026 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
GKGamze Karataş
Gamze Karataş
AÇAkın Çakır
Akın Çakır
ÖAÖznur Aday
Öznur Aday
TUTahsin Uzundede
Tahsin Uzundede
FKFurkan Kirik
Furkan Kirik
MEMustafa Nuri Elçioğlu
Mustafa Nuri Elçioğlu
Long-Term Intravitreal Dexamethasone Implant Monotherapy in Naïve Patients with Diabetic Macular Edema - Turkish Journal of Ophthalmology

24 June 2026 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
GKGamze Karataş
Gamze Karataş
AÇAkın Çakır
Akın Çakır
ÖAÖznur Aday
Öznur Aday
TUTahsin Uzundede
Tahsin Uzundede
FKFurkan Kirik
Furkan Kirik
MEMustafa Nuri Elçioğlu
Mustafa Nuri Elçioğlu
Reply - Turkish Journal of Ophthalmology